H pylori seroprevalence in patients with lung cancer

World J Gastroenterol. 2007 Apr 28;13(16):2349-51. doi: 10.3748/wjg.v13.i16.2349.


Aim: To assess H pylori seroprevalence in lung cancer and determine whether there is a potential association between lung cancer and H pylori infection.

Methods: The study was conducted on forty consecutive patients with lung cancer, confirmed by pathology (32 men, 8 women; mean age 55.50+/-11.91 years, range 16-77 years). Forty healthy subjects (25 men, 15 women; mean age 43.08+/-12.60 years, range 20-79 years) from the patients' family members were matched to each case subject on the basis of age and socioeconomic status. H pylori infection was detected with a commercially available immunoglobulin G (IgG) enzyme-linked immunosorbent assay (Trinity kit, Biotech co., USA), previously validated in adults (86% sensitivity, 96% specificity) against a gold standard of culture and histology.

Results: H pylori seropositivity was present in 52.5% of patients with lung cancer in comparison to 45.0% of healthy control subjects. Although H pylori seropositivity was more frequent in lung cancer patients than in controls, the difference did not reach statistical significance (OR=1.35, 95% CI=0.56-3.25; P=0.65). In addition, there was no significant difference between cases and controls in terms of gastrointestinal symptoms.

Conclusion: The earlier described association between H pylori infection and lung cancer was not supported in this study. Further studies with larger sample sizes should be undertaken to assess the frequency of H pylori infection in patients with lung cancer and their potential association.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Bacterial / blood*
  • Case-Control Studies
  • Female
  • Helicobacter Infections / blood
  • Helicobacter Infections / complications
  • Helicobacter Infections / epidemiology*
  • Helicobacter pylori / immunology*
  • Humans
  • Lung Neoplasms / blood
  • Lung Neoplasms / epidemiology
  • Lung Neoplasms / microbiology*
  • Male
  • Middle Aged
  • Risk Factors
  • Seroepidemiologic Studies


  • Antibodies, Bacterial